The Federal Trade Commission and four states on Wednesday sued a trade group for gender-affirming care providers, claiming it made false and unsubstantiated claims about the benefits of transition-related services.
Why it matters: The complaint in a federal court in Texas opens another front in the Trump administration's efforts to limit the availability of puberty blockers, hormone therapies and other forms of care.
More reports ofworkplace violence in hospitals and clinics are reviving calls for a federal standard to protect nurses, social workers and others in medical settings.
Why it matters: Health care workers have been among the likeliest to experience threats or be assaulted on the job since the onset of the pandemic.
Nursing home staffing levels have mostly bounced back to pre-pandemic levels after cratering during the health emergency.
Why it matters: The nursing home industry pointed to staffing shortages and difficulty hiring new workers in its successful fight against the Biden administration's first-ever minimum staffing requirements.
The Trump administration took another step toward pivoting away from animal testing in biomedical research on Monday, establishing an office within the National Institutes of Health to develop and promote 3D human tissue models, computational tools and other alternatives.
Why it matters: It makes good on a pledge NIH director Jay Bhattacharya made in April 2025 and follows the launch of a Food and Drug Administration pilot program to phase out some animal testing requirements for antibody therapies and other drugs.
Senate Democrats on Tuesday are unveiling a proposal to expand Medicare drug price negotiations, in a bid to counter President Trump's election-year messaging on health care affordability.
Why it matters: High prescription drug prices are a key concern for voters ahead of the midterms — one Trump is trying to address through voluntary pricing deals with leading drug companies and with the TrumpRx website.
